Modelling imperfect adherence to HIV induction therapy

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Miron, Rachelle E ^a   Smith, Robert J ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL RESEARCH; COMPUTER SIMULATION; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; PATIENT COMPLIANCE; PRACTICE GUIDELINE; VIRUS LOAD; VIRUS REPLICATION; ANTIVIRAL RESISTANCE; STATISTICAL MODEL; STATISTICS; UNITED STATES;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; MODELS, STATISTICAL; UNITED STATES;

EID: 77949555521     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-6     Document Type: Article

References (48)

1. Steinbrook R. The AIDS Epidemic - A Progress Report from Mexico City. N Engl J Med 2008, 359:885-887. 10.1056/NEJMp0805761, 18753643.
2. McCune J. The dynamics of CD4+T-cell depletion in HIV disease. Nature 2001, 410:974-979. 10.1038/35073648, 11309627.
3. Yeni PG, Hammer SM, Hirsch M, Saag M, Schechter M, Carpenter CCJ, Fischi MA, Gatell JM, Gazzard BG, Jacobsen D, Katzenstein DA, Montaner JSG, Richman DD, Schooley RT, Thompson MA, Vella S, Volberding PA. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society - USA Panel. JAMA 2004, 292:251-265. 10.1001/jama.292.2.251, 15249575.
4. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999, 341:1865-1873. 10.1056/NEJM199912163412501, 10601505.
5. Moyle G. Protease inhibitor-sparing regimens: new evidence strengthens position. J Acq Immun Def Synd 2003, 33(Suppl 1):17-25.
6. Atlice FL, Friedland GH. The era of adherence to HIV therapy. Ann Intern Med 1998, 129:503-505.
7. Wahl LM, Nowak MA. Adherence and drug resistance: predictions for therapy outcome. Proc R Soc B 2000, 267:835-843. 10.1098/rspb.2000.1079, 1690604, 10819155.
8. Philips AN, Youle M, Johnson M, Loveday C. Use of stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development. AIDS 2001, 15:2211-2220. 10.1097/00002030-200111230-00001, 11698693.
9. Tchetgen E, Kaplan EH, Friedland GH. Public health consequences of screening patients for adherence to highly active antiretroviral therapy. J AIDS 2001, 26:118-129.
10. Huang Y, Rosenkranz S, Wu H. Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. Math Biosci 2003, 184:165-186. 10.1016/S0025-5564(03)00058-0, 12832146.
11. Huang Y, Liu D, H W. Hierarchical Bayesian methods for estimation of parameters in longitudinal HIV dynamic system. Biometrics 2004, 62:413-423.
12. Ferguson NM, Donnelly CA, Hooper J, Ghani AC, Fraser C, Bartley L. Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients. J R Soc Interface 2005, 2:349-363. 10.1098/rsif.2005.0037, 1578278, 16849193.
13. Smith RJ. Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges?. Proc R Soc B 2006, 273:617-624. 10.1098/rspb.2005.3352, 1560063, 16537134.
14. Krakovska O, Wahl LM. Optimal drug treatment regimens for HIV depend on adherence. J Theor Biol 2007, 246:499-509. 10.1016/j.jtbi.2006.12.038, 17320115.
15. Friedland GH, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 1999, 13(Suppl 1):61-72.
16. Reijers MH, Weverling GJ, Jurriaans S, Wit FW, Weigel HM, Ten Kate RW, Mulder JW, Frissen PH, van Leeuwen R, Reiss P, Schuitemaker H, de Wolf F, Lange JM. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication study. Lancet 1998, 352:185-190. 10.1016/S0140-6736(98)06193-5, 9683207.
17. Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, Ioannidis JP, Holohan MK, Leavitt R, Coone G, Richman DD. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med 1998, 339:1261-1268. 10.1056/NEJM199810293391801, 9791141.
18. Pialoux G, Raffi F, Brun-Vezinet F, Meiffrédy V, Flandre P, Gastaut J, Dellamonica P, Yeni P, Delfraissy J, Aboulker J. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med 1998, 339:1269-1276. 10.1056/NEJM199810293391802, 9791142.
19. Descamps D, Flandre P, Calvez V, Peytavin G, Meiffrédy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F, Brun-Vézinet F. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA 2000, 283:205-211. 10.1001/jama.283.2.205, 10634336.
20. Curlin M, Iyer S, Mittler J. Optimal timing and duration of induction therapy for HIV-1 infection. PLoS Comput Biol 2007, 3(7):e133. 10.1371/journal.pcbi.0030133, 1914372,1914372, 17630827.
21. Havlir D, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP, Richman DD. Drug Susceptibility in HIV infection after Viral Rebound in Patients Recieving Indinavir-Containing Regimens. JAMA 2000, 283:299-234.
22. Pai N, Lawrence J, Reingold AL, Tulsky J. Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults. Cochrane Database of Systematic Reviews 2006, 3:CD006148.
23. Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy. Social Science & Medicine 2000, 50:1599-1605.
24. Curlin ME, Wilkin T, Mittler J. Induction-maintenance therapy for HIV-1 infection. Future HIV Therapy 2008, 2:175-185.
25. Cohen CJ, Colson AE, Sheble-Hall AG, McLaughlin KA, Morse GD. Pilot Study of a Novel Short-Cycle Antiretroviral Treatment Interruption Strategy: 48-Week Results of the Five-Days-On, Two-Days-Off (FOTO) Study. HIV Clin Trials 2007, 8:19-23. 10.1310/hct0801-19, 17434845.
26. Smith RJ, Wahl LM. Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects. Bull Math Biol 2005, 67:783-813. 10.1016/j.bulm.2004.10.004, 15893553.
27. Smith RJ, Aggarwala BD. Can the viral reservoir of latently infected CD4+ T cells be eradicated with antiretroviral drugs?. J Math Biol 2009, 59:697-715. 10.1007/s00285-008-0245-4, 19165438.
28. Bainov DD, Simeonov PS. Systems with Impulsive Effect 1989, Chichester: Ellis Horwood Ltd.
29. Bainov DD, Simeonov PS. Impulsive differential equations: periodic solutions and applications 1993, Burnt Mill: Longman Scientific and Technical.
30. Bainov DD, Simeonov PS. Impulsive Differential Equations: Asymptotic Properties of the Solutions 1995, Singapore: World Scientific.
31. Lakshmikantham V, Bainov DD, Simeonov PS. Systems with Impulsive Effect 1989, Singapore: World Scientific.
32. El-Sadr WM, Lundgren JD. Strategies for Management of Antiretroviral Therapy (SMART) Study Group CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355(22):2283-2296. 10.1056/NEJMoa062360, 17135583, Strategies for Management of Antiretroviral Therapy (SMART) Study Group.
33. DART Trial Team Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl. AIDS 2008, 22(2):237-247. 10.1097/QAD.0b013e3282f2d760, 18097226, DART Trial Team.
34. Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips A, Lundgren J. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med 2007, 8:96-104. 10.1111/j.1468-1293.2007.00436.x, 17352766.
35. Li X, Margolick J, Conover C, Badri S, Riddler SA, Witt MD, Jacobson LP. Interruption and Discontinuation of Highly Active Antiretroviral Therapy in the Multicenter AIDS Cohort Study. JAIDS 2005, 38:320-328.
36. Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, Gallo C, Azzoni L, Foulkes A, Thiel B, Pistilli M, Mackiewicz A, Shull J, Montaner LJ. Randomized, Controlled Trial of Therapy Interruption in Chronic HIV-1 Infection. PLoS Medicine 2004, 1(3):e64. 10.1371/journal.pmed.0010064, 539050, 15630469.
37. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2008, 1-139., http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
38. Ait-Khaled M, Stone C, Amphlett G, Clotet B, Staszewski S, Katlama C, Tisdale M, . CNA3002 International Study Team M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS 2002, 16:1686-1689. 10.1097/00002030-200208160-00017, 12172093, CNA3002 International Study Team.
39. Smith RJ, Schwartz EJ. Predicting the potential impact of a cytotoxic T-lymphocyte HIV vaccine: how often should you vaccinate and how strong should the vaccine be?. Math Biosci 2008, 212:180-187. 10.1016/j.mbs.2008.02.001, 18359048.
40. Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, Kottilil S, Moir S, Mican JM, Mullins JI, Ward DJ, Kovacs JA, Mannon PJ, Fauci AS. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008, 197:714-720. 10.1086/527324, 18260759.
41. Scott L, Perry C. Delavirdine - A review of its use in HIV infection. Drugs 2000, 60:1411-1444. 10.2165/00003495-200060060-00013, 11152019.
42. Perry C, Noble S. Didanosine - An update review of its use in HIV infection. Drugs 1999, 58:1099-1135. 10.2165/00003495-199958060-00009, 10651392.
43. Bhana N, Ormrod D, Perry C, Figgitt D. Zidovudine - A review of its use in management of vertically-aquired pediatric HIV infection. Drugs 2002, 4:515-553.
44. Hervey P, Perry C. Abacavir - A review of its clinical potential in patients with HIV infection. Drugs 2000, 60:447-479. 10.2165/00003495-200060020-00015, 10983741.
45. Frampton J, Perry C. Emtricitabine - A review of its use in management of HIV infection. Drugs 2006, 65:1427-1448.
46. Moore KHP, Barrett JE, Shaw S, Pakes GE, Churchus R, Kapoor A, Barry MG, D B. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS 1999, 13:2239-2250. 10.1097/00002030-199911120-00006, 10563709.
47. Fletcher C, Brundage R, Remmel R, Page L, Weller D, Calles N, Simon C, Kline M. Pharmacologic characteristics of indinivir, didanosine, stavudine, in human immunodeficiency virus-infected children receiving combination therapy. Antimicrobial Agents and Chemotherapy 2000, 44:1029-1034. 10.1128/AAC.44.4.1029-1034.2000, 89808, 10722507.
48. Hawkins T, Veikley W, St Claire R, Guyer B, Clark N, Kearney B. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Defic Syndr 2001, 39:406-411.